Last update: Jan. 24, 2017

木聚硫钠

Very Low Risk for breastfeeding


Compatible.
Not risky for breastfeeding or infant.

Sulfated polysaccharide of plant origin with anticoagulant and fibrinolytic properties similar to heparin. Topical, oral and parenteral administration (subcutaneous, intramuscular or intravenous).
Orally used for pain relief of the urinary tract on interstitial cystitis.
Topically used on superficial venous disorders, hemorrhoids and hematomas.

At latest update relevant published data on its excretion into breast milk were not found.

Because of a high molecular weight, excretion into breastmilk in significant amounts seems very unlikely.
A low or not at all oral bioavailability (Faaij 1999, Simon 2005) makes it seems difficult the pass into the infant’s plasma through the breast milk ingested, except for premature infants and immediate neonatal period, in which there may be an increased intestinal permeability.

Do not apply it on the chest to prevent the infant from ingesting it; if necessary, do it after a feeding and clean it up thoroughly with water before the next one.

Alternatives

We do not have alternatives for 木聚硫钠 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

木聚硫钠 is Pentosan Polysulfate Sodium in Chinese.

Is written in other languages:

木聚硫钠 is also known as

Tradenames

Main tradenames from several countries containing 木聚硫钠 in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 0 - 6 %
Molecular weight 4.000 - 6.000 daltons
Tmax 3 hours
T1/2 20 hours

References

  1. AEMPS. Pentosano. Ficha técnica. 2007 Full text (in our servers)
  2. Simon M, McClanahan RH, Shah JF, Repko T, Modi NB. Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers. Xenobiotica. 2005 Abstract
  3. FDA. Pentosan. Prescribing Information. 2002 Full text (in our servers)
  4. Faaij RA, Srivastava N, van Griensven JM, Schoemaker RC, Kluft C, Burggraaf J, Cohen AF. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. Eur J Clin Pharmacol. 1999 Abstract
  5. Peters M, Witvrouw M, De Clercq E, Ruf B. Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients. AIDS. 1991 Abstract
  6. Dawes J, Prowse CV, Pepper DS. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res. 1986 Abstract

Total visits

506

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM